Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab-based regimen versus conventional therapy for remission induction in EGPA
2016-000275-25Phase 3Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Apr 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rituximab, cyclophosphamide, mesna and prednisone in eosinophilic granulomatosis with polyangiitis (EGPA) (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Complete remission at day 180. Started Apr 2016; status: completed.
02
Drugs
rituximabcyclophosphamidemesnaprednisone
03
Conditions
eosinophilic granulomatosis with polyangiitis (EGPA)
Beyond the preview
Go deeper on 2016-000275-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000275-25.